Immunotherapy plus chemo before surgery for esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of immunotherapy (sintilimab) and chemotherapy given before surgery for esophageal cancer that can be surgically removed. The goal is to see if this approach helps shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your esophageal tumor must be able to be removed with surgery.
- You must not have had any previous chemotherapy or immunotherapy for this cancer.
- You must be between 18 and 75 years old.
- You must be physically active enough to care for yourself (ECOG score 0 or 1).
- No active bleeding, trouble swallowing, or major stomach/bowel problems.
- No history of bleeding disorders or recent serious bleeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of an immunotherapy drug (sintilimab) with chemotherapy given before surgery for a type of esophageal cancer called squamous cell carcinoma. The goal is to see if this treatment shrinks the tumor and improves outcomes.
This trial tests giving the immunotherapy drug sintilimab together with chemotherapy before and after surgery for esophageal squamous cell carcinoma. It aims to see if this combination can help improve outcomes for patients whose tumors can be surgically removed.
This trial tests whether giving the immunotherapy drug sintilimab together with standard chemotherapy and a growth factor injection before surgery can help people with a certain type of esophageal cancer (squamous cell carcinoma) that is still removable. The goal is to improve treatment outcomes before the operation.
This trial tests a short course of radiation combined with the immunotherapy drug Sintilimab before surgery for esophageal cancer. The goal is to see if this combination makes the tumor shrink more and improves treatment results.
This trial tests a drug called Adebrelimab combined with chemotherapy before surgery for esophageal cancer. It aims to shrink the tumor and make it easier to remove completely.
This trial studies giving immunotherapy (anti–PD-1) together with chemotherapy before surgery for certain locally advanced esophageal squamous cell cancer. The goal is to improve how well the tumor responds before and after the operation.
Hear when a new Resectable Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.